Logo image of ACHL

ACHILLES THERAPEUTICS PL-ADR (ACHL) Stock Fundamental Analysis

NASDAQ:ACHL - Nasdaq - US00449L1026 - ADR - Currency: USD

1.48  +0.01 (+0.68%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to ACHL. ACHL was compared to 551 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for ACHL as it has an excellent financial health rating, but there are worries on the profitability. ACHL does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ACHL had negative earnings in the past year.
In the past year ACHL has reported a negative cash flow from operations.
In the past 5 years ACHL always reported negative net income.
In the past 5 years ACHL always reported negative operating cash flow.
ACHL Yearly Net Income VS EBIT VS OCF VS FCFACHL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 -20M -40M -60M

1.2 Ratios

Looking at the Return On Assets, with a value of -54.52%, ACHL is in line with its industry, outperforming 44.91% of the companies in the same industry.
The Return On Equity of ACHL (-64.84%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -54.52%
ROE -64.84%
ROIC N/A
ROA(3y)-31.57%
ROA(5y)-24.64%
ROE(3y)-35.39%
ROE(5y)-27.5%
ROIC(3y)N/A
ROIC(5y)N/A
ACHL Yearly ROA, ROE, ROICACHL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 -10 -20 -30 -40 -50

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ACHL so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ACHL Yearly Profit, Operating, Gross MarginsACHL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023

More info and screens

7

2. Health

2.1 Basic Checks

ACHL has more shares outstanding than it did 1 year ago.
ACHL has more shares outstanding than it did 5 years ago.
ACHL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ACHL Yearly Shares OutstandingACHL Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M
ACHL Yearly Total Debt VS Total AssetsACHL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 100M 200M 300M

2.2 Solvency

Based on the Altman-Z score of -2.60, we must say that ACHL is in the distress zone and has some risk of bankruptcy.
ACHL has a Altman-Z score (-2.60) which is comparable to the rest of the industry.
There is no outstanding debt for ACHL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -2.6
ROIC/WACCN/A
WACCN/A
ACHL Yearly LT Debt VS Equity VS FCFACHL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 100M 200M

2.3 Liquidity

A Current Ratio of 6.04 indicates that ACHL has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 6.04, ACHL is in the better half of the industry, outperforming 63.86% of the companies in the same industry.
A Quick Ratio of 6.04 indicates that ACHL has no problem at all paying its short term obligations.
With a decent Quick ratio value of 6.04, ACHL is doing good in the industry, outperforming 64.39% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.04
Quick Ratio 6.04
ACHL Yearly Current Assets VS Current LiabilitesACHL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 12.70% over the past year.
EPS 1Y (TTM)12.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-14.29%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, ACHL will show a small growth in Earnings Per Share. The EPS will grow by 0.30% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y89.45%
EPS Next 2Y38.91%
EPS Next 3Y-17.11%
EPS Next 5Y0.3%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ACHL Yearly Revenue VS EstimatesACHL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2031 20M 40M 60M 80M
ACHL Yearly EPS VS EstimatesACHL Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 -2 -4 -6 -8

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ACHL. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ACHL. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ACHL Price Earnings VS Forward Price EarningsACHL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ACHL Per share dataACHL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

A cheap valuation may be justified as ACHL's earnings are expected to decrease with -17.11% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.91%
EPS Next 3Y-17.11%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ACHL!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ACHILLES THERAPEUTICS PL-ADR

NASDAQ:ACHL (3/20/2025, 8:00:00 PM)

1.48

+0.01 (+0.68%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2024-11-14/bmo
Earnings (Next)04-02 2025-04-02/amc
Inst Owners86.1%
Inst Owner Change-0.27%
Ins Owners6.51%
Ins Owner ChangeN/A
Market Cap63.20M
Analysts40
Price Target6.12 (313.51%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-6.41%
Min EPS beat(2)-14.78%
Max EPS beat(2)1.96%
EPS beat(4)2
Avg EPS beat(4)-46.83%
Min EPS beat(4)-211.02%
Max EPS beat(4)36.52%
EPS beat(8)3
Avg EPS beat(8)-30.26%
EPS beat(12)6
Avg EPS beat(12)-14.42%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)5.26%
EPS NY rev (1m)0%
EPS NY rev (3m)88.54%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.61
P/tB 0.61
EV/EBITDA N/A
EPS(TTM)-1.65
EYN/A
EPS(NY)-0.12
Fwd EYN/A
FCF(TTM)-1.5
FCFYN/A
OCF(TTM)-1.48
OCFYN/A
SpS0
BVpS2.42
TBVpS2.42
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -54.52%
ROE -64.84%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-31.57%
ROA(5y)-24.64%
ROE(3y)-35.39%
ROE(5y)-27.5%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 17.12%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.04
Quick Ratio 6.04
Altman-Z -2.6
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)152.93%
Cap/Depr(5y)462.21%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)12.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-14.29%
EPS Next Y89.45%
EPS Next 2Y38.91%
EPS Next 3Y-17.11%
EPS Next 5Y0.3%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y8.32%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year7.37%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-3.39%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-16.14%
OCF growth 3YN/A
OCF growth 5YN/A